| Literature DB >> 30800252 |
Mohammad Mehdi Heidari1, Mehdi Hadadzadeh2, Hossein Fallahzadeh3.
Abstract
BACKGROUND: The Angiotensin Converting Enzyme (ACE) Insertion/Deletion and rs-4343 gene polymorphisms could be associated with pathogenesis of essential hypertension and cardiovascular disorders and Coronary Artery Disease (CAD). In the present study, a fast and novel approach of multiplex Tetra-Primer Amplification Refractory Mutation System-PCR (T-ARMS-PCR) was developed for simultaneous detection of two SNPs including ACE I/D (rs4340) and 2350A>G (rs4343) of Angiotensin Converting Enzyme (ACE) gene.Entities:
Keywords: Angiotensin converting enzyme (ACE) gene; Coronary artery disease; Insertion/Deletion polymorphism
Year: 2019 PMID: 30800252 PMCID: PMC6359703
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
The summary of the clinical characteristics of coronary atherosclerosis patients and controls
| 73 | 69 | |
| 52.6±7.2 | 51.9± 6.7 | |
| 26 | 22 | |
| 26.5±2.6 | 25.3±2.1 | |
| 208.6±53.4 | 182.3±46.4 | |
| 125.4±44.8 | 112.9±43.9 | |
| 42.8±8.9 | 48.7±12.5 | |
| 201.2±108.2 | 149.3±92.5 | |
| 153.2±0.6 | 116.9±0.3 | |
| 97.5±0.4 | 78.3±0.4 |
p-value <0.05
PCR primer sequences
| Forward inner primer A allele | 5'-TCTGACGAATGTGATGGCCCCA-3' | 271 | |
| Reverse inner primer G allele | 5'-AACAGGTCTTCATATTTCCGGTAC-3' | 200 | |
| Forward outer primer | 5'-GAGGCTGAGATGGAAGGATTG-3' | 712 | |
| Reverse outer primer | 5'-GCTCTCCCAACACCACATTAC-3' | 424 | |
Figure 1.Schematic illustration of primer interactions for ACE Multiplex T-ARMS-PCR assay. Fo and Ro are outer primers acting as control primers, and Fi and Ri are inner primers for 2350 nucleotide substitution (rs4343).
Amplification patterns observed and those expected according to ACE polymorphisms genotypes
| DA/DA | DA/DG | DG/DG | DA/IA | IA/DG | IG/DA | IG/DG | IA/IA | IA/IG | IG/IG | |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 712 | 712 | 712 | 712 | 712 | 712 | 712 | |
| - | - | - | - | - | 488 | 488 | - | 488 | 488 | |
| 424 | 424 | 424 | 424 | 424 | 424 | 424 | - | - | - | |
| 271 | 271 | - | 271 | 271 | 271 | - | 271 | 271 | - | |
| - | 200 | 200 | - | 200 | - | 200 | - | - | - | |
D and I: Deletion/Insertion allele (rs4340 SNP); A and G: wild type and mutant allele (rs4343 SNP).
Figure 2.Results of T-ARMS-PCR of ACE polymorphisms (rs4043 and rs4343). Lanes 1 and 6: DDGG genotype, lanes 2, 3 and 4: IIAA genotype and lane 5: DIAG (IA/DG) genotype.
Genotype and allele frequencies of ACE variants in patients and controls
| DD | 69 (46.6%) | 73 (54.1%) | 1 | |
| DI | 54(36.5 %) | 47 (34.8%) | 1.076 (0.661–1.751) | 0.805 |
| II | 25 (16.9%) | 15 (11.1%) | 1.626 (0.817–3.235) | 0.176 |
| DD | 69 (46.6%) | 73 (54.1%) | ||
| DI+ II | 79 (53.4%) | 62 (45.9%) | 0.742 (0.465–1.184) | 0.235 |
| DD+DI | 123 (83.1%) | 120 (88.9%) | ||
| II | 25 (16.9%) | 15 (11.1%) | 0.615 (0.309–1.223) | 0.176 |
| DD+ II | 94 (63.5%) | 88 (65.2%) | ||
| DI | 54 (36.5%) | 47 (34.8%) | 0.930 (0.571–1.513) | 0.805 |
| D | 192 (64.9%) | 193 (71.5%) | ||
| I | 104 (35.1%) | 77 (28.5%) | 0.737 (0.516–1.052) | 0.104 |
| AA | 64 (43.2%) | 62 (45.9%) | 1 | |
| AG | 61 (41.2%) | 55 (40.7 %) | 1.020 (0.635–1.639) | 1.000 |
| GG | 23 (15.6%) | 18 (13.4%) | 1.195 (0.614–2.329) | 0.617 |
| AA | 64 (43.2%) | 62 (45.9%) | ||
| AG+GG | 84 (56.8 %) | 73 (54.1%) | 0.897 (0.561–1.434) | 0.720 |
| AA+AG | 125 (84.4%) | 117 (86.6%) | ||
| GG | 23 (15.6%) | 18 (13.4%) | 0.769 (0.399–1.483) | 0.508 |
| AA+GG | 87 (58.8%) | 80 (59.3%) | ||
| AG | 61 (41.2%) | 55 (40.7 %) | 0.981 (0.610–1.576) | 1.000 |
| A | 189 (63.8%) | 179 (66.3%) | ||
| G | 107 (36.2%) | 91 (33.7%) | 0.898 (0.635–1.270) | 0.597 |
OR, odds ratio; CI, Confidence interval.
Haplotype analysis of AGT polymorphisms in CAD patients and controls
| DA/DA | 31 | 35 | 1 | ||
| DA/DG | 17 | 18 | 0.844 (0.415–1.713) | 0.719 | |
| DG/DG | 17 | 16 | 0.965 (0.467–1.996) | 1.000 | |
| DA/IA | 18 | 19 | 0.845 (0.423–1.688) | 0.725 | |
| DA/IG | 23 | 16 | 1.369 (0.689–2.717) | 0.392 | |
| DG/IA | 13 | 14 | 0.832 (0.376–1.841) | 0.689 | |
| DG/IG | 4 | 2 | 1.847 (0.333–10.251) | 0.686 | |
| IA/IA | 15 | 8 | 1.790 (0.734–4.368) | 0.276 | |
| IA/IG | 8 | 7 | 1.045 (0.368–2.963) | 1.000 | |
| IG/IG | 2 | 0 | 1.014 (0.995–1.033) | 0.499 | |
OR, odds ratio; CI, Confidence interval.
The results of different studies on ACE gene polymorphisms
| Iran | 183 | 21.31 | 39.89 | 38.79 | 41.25 | 58.74 | 0.092 | |
| Iran | 676 | 14.3 | 38.8 | 46.9 | 33.7 | 66.3 | 0.494 | |
| Saudi Arabia | 100 | 17 | 30 | 53 | 32 | 68 | 0.40 | |
| India (Kashmiri) | 52 | 23.7 | 30.77 | 46.15 | 38.46 | 61.53 | 0.24 | |
| France | 199 | N.A. | N.A. | N.A. | 42.7 | 57.3 | N.A. | |